Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 4 8 Farzad Mollahoseini Foomani Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Mahammad Hadi Sadeghain Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Saeede Bagheri Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran Zahra Badiee Pediatrics Department, Doctor Sheikh Hospital, Mashhad University of Medical Sciences, Mashhad, Iran Reihane Bazargani Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Zahra Aryanpour Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Saeid Hallajian Blood Transfusion Organization Research Center, Iranian Blood Transfusion Organization, Mashhad, Iran Seyyede Fatemeh Shams Blood Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 2020 10 31 2021 05 01 Background:  Thalassemia is an inherited disease with anemia and hemolysis. Blood transfusion is a routine treatment for thalassemia patients; alloimmunization is one of the complications of blood transfusion, which is very serious for these patients, especially girls and young women.    Materials and Methods:  Four hundred forty-six thalassemia patients were examined in this cross-sectional study. Demographic information of patients was extracted and recorded. The phenotype of ABO, Rh, and Kell antigens (tube method) with antisera from IMMUNDIANOSTICA Company (Germany) and the frequency of alloantibodies were determined. Results: 55.8% of the studied individuals were male and 44.2% were female. The mean age of the studied patients was 19.94±10.63.  The alloantibodies were detected in 7.5% of pack cell receivers. The most prevalent phenotype of the ABO system was the O blood group (37.4%), and the most abundant antigen of the Rh group was ‘e’, which was found in 99.8% of the studied population. The most frequently detected alloantibody was Anti K (38.2%); concerning kell phenotype, (K_k+) and (K+k+) were found in 99.3% and 0.7% of patients, respectively. The frequency of Anti-D, Anti-C, Anti-c, and Anti-E was 23.5%, 14.7%, 2.9%, and 14.7%, respectively. Conclusion: According to the results of this paper, finding the compatible pack cells in terms of Kell and Rh systems antigens in addition to the ABO blood group is recommended to decrease the rate of alloantibodies in thalassemia patients. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1453 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1453/957

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 1 3 Ali Akbar Pourfathollah Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran Karim Shamsasenjan Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Mahmoud Hadipour Dehshal Mehregan Pharmacy, Tehran, Iran 2022 08 22 2023 01 07 No Abstracts  No Abstracts  No Abstracts  https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1899 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1899/956

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 56 62 Rachel Hicks Brookdale University Hospital Medical Center Mohammed Alsabri Brookdale University Hospital Medical Center Mario Peichev Brookdale University Hospital Medical Center Viswanathan Kusum Brookdale University Hospital Medical Center 2020 11 02 2021 05 10 Periorbital swelling is a clinical presentation with a broad differential and potentially deleterious consequences. Causes range from benign, including allergic reaction, to vision- and life-threatening, including orbital cellulitis and orbital infarction. The recent climate of SARS-CoV-2 has further complicated this differential, as the virus poses broad clinical presentations with new manifestations reported frequently. Rapid identification of the underlying etiology is crucial, as treatment approaches diverge greatly. Here, we report the case of an African American adolescent male with a history of homozygous sickle cell anemia presenting to an inner city hospital with bilateral periorbital swelling amid the coronavirus pandemic. Differentials including orbital cellulitis, COVID-MIS-C, orbital inflammatory syndrome, Hoagland sign, and orbital infarction secondary to sickle cell crisis are contrasted. We contrast our case with 12 case reports of orbital infarction in the setting of sickle cell crisis within the past 10 years, highlighting how these presentations, along with commonly reported findings of orbital infarction, compare with our patient. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1462 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1462/963

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 9 17 EN Shahram Shojaei Bistoon Hospital, Kermanshah, Iran Mozaffar Aznab Department of Internal Medicine, Talaghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran Amirmasoud Rahimi Kermanshah University of Medical Sciences, Kermanshah, Iran Seyed Mojtaba Ahmadi Department of Clinical Psychology School of Medicine, Kermanshah University of Medical Science, Kermanshah, Iran Kumars Eslampia Department of Surgery, Bistoon Hospital, Kermanshah, Iran Arash Golpazir Department of Surgery, Cancer Surgery, Kermanshah University of Medical Sciences, Kermanshah, Iran Masoud Iravani Masoud Gastroenterology and Liver Clinic, Tehran, Iran 2020 09 23 2021 05 09 Background: This study aimed to evaluate the significance of tumor lymphocyte infiltration (TIL) and the number of CD8+ T cells in breast cancer and their relationship with the other clinicopathological factors and overall survival (OS) was investigated. Materials and Methods: The studied samples were breast cancer patients (2005-2017) referring to the medical oncology departments for treatment. Pathologic samples of breast cancer patients were evaluated in terms of TIL and positive immunohistochemical staining for CD8 cytotoxic cells. Results: 299 patients were entered into the study, 3 male and 296 female. Their mean follow-up period was 61 months. Statistical findings indicated that lymph involvement is more accompanied by low TIL within the tumor (0.011). Correlations were observed between the estrogen, progesterone receptors, P53 state, and TIL; which were significant by P-value<0.049, P-value=0.024, P-value =0.002, respectively. With any Ki67 value, the number of patients with less than 30% TIL was more considerable than the two other groups with lymphocyte cut-off of 30-50% and more than 50%. Comparison of the OS of patients with positive and negative CD8 cytotoxic lymphocytes in 45 patients with lymphocyte infiltration of equal or more than 40% showed that the OS results were in favor of patients with CD8+ cytotoxic lymphocyte (0.022). Out of 299 patients, 17 died. Conclusion: Our findings showed that in cases of CD8+ cytotoxic lymphocytes in tumors, the OS of the patients will be enhanced which can act as an independent.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1432 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1432/958

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 18 27 Seyedeh Sahar Mortazavi Farsani Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Dina Sadeghizadeh Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Sadegh Babashah Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran Fariba Rad Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran Majid Sadeghizadeh 1) Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran 2) Alborz Nanomed Technology Company, Tehran, Iran 2020 12 31 2021 05 31 Background: Megakaryopoiesis is characterized by progressive polyploidization and the expression of megakaryocytic markers. Numerous transcription factors and physiological signaling pathways regulate this phenomenon. Megakaryocyte differentiation induction in the K562 cell line and hematopoietic stem cells via nanocurcumin drug has been identified in our previous study. K562 cells are typical Chronic Myelogenous Leukemia (CML) cells that are resistant to apoptosis and express the bcr-abl fusion gene. These cells have the potential to differentiate into erythrocytes and megakaryocytes. Curcumin is well known as a component with strong potential to alter NFκB activity in various cells. NFκB pathway regulates various genes such as apoptotic and immune response genes. The aim of the current study is to evaluate the possible role of nanocurcumin in NFκB pathway regulation during the megakaryopoiesis process in the K562 cell line. Materials and Methods: Megakaryocyte markers expression and phenotype alteration of nanocurcumin-treated K562 cells have been detected by flow cytometry and microscopy imaging. The nuclear level of the RelA (p65) subunit of NFκB was determined by western blot test in K562 cells during megakaryopoiesis induction via nanocurcumin treatment at different times. The expression of NFκB target genes including c-MYC, BAX, and NQO1 was also analyzed in nanocurcumin-treated K562 cells by quantitative RT-PCR assay at different times. Results: It was demonstrated that nanocurcumin leads to an increase in NFκB activity transiently during megakaryocyte differentiation, which is followed by a change in the expression of c-MYC, BAX, and NQO1 target genes. Conclusion: The NFκB pathway can be considered a new pathway for inducing megakaryocyte differentiation by nanocurcumin for the purposes of in vitro and in vivo megakaryopoiesis experiments. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1514 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1514/959

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 28 38 Carlos Atencia-Flórez Department of Internal Medicine, University of Antioquia School of Medicine, Medellín, Colombia Catalina Quintero-Valencia Laboratorio Integrado de Medicina Especializada – LIME, Medellin (Antioquia), Colombia María Mondragón-Arismendy Laboratorio Integrado de Medicina Especializada – LIME, Medellin (Antioquia), Colombia Andrés Cardona-Arias University of Antioquia School of Medicine, the SURA Healthcare Insurance Company, Medellin (Antioquia), Colombia Carlos Regino-Agamez Department of Internal Medicine, University of Antioquia School of Medicine, Medellín, Colombia Julián Vélez-Urrego San Vicente Foundation University Hospital, Medellin (Antioquia), Colombia 2021 01 08 2021 05 05 Background:  Multiple myeloma is the second most common hematologic malignancy after lymphomas. Few studies have characterized significant and full variables at the time of diagnosis of multiple myeloma in Colombia, and there is no data evaluating patients for follow-up. Materials and Methods:  A retrospective cohort study is presented, describing the clinical, laboratory, cytometric, and cytogenetic characteristics of patients with a de novo diagnosis of multiple myeloma evaluated in a reference hematology laboratory attached to a highly complex hospital in Medellín, Colombia.  We follow them until death as a main outcome. Results:  A total of 170 patients with a de novo diagnosis of multiple myeloma were collected from a database of 421 patients with different monoclonal gammopathies. Mainly, it was found that 50.8% of the patients were men; the median age was 62 years; 65.4% had secretion of the IgG kappa; half of the patients presented International Staging System (ISS) Stage III. The β2 macroglobulin >4 mg/L and creatinine >2 mg/dl were the main variables significantly associated with survival (Hazard Ratio (HR) 2.4 and 2, respectively). Eighty-five percent of patients presented with bone lytic lesion involvement and less than 3% with extramedullary involvement. Conventional Banding Karyotype (CBK) genetic risk assessment yield was poor, compared with although scarce data regarding Cytogenetic risk assessment based on Fluorescence in-situ Hybridization (FISH). Conclusion:  The clinical profile of the patients with a de novo diagnosis of multiple myeloma in our cohort is similar to that described in international studies. The diagnosis of multiple myeloma was documented at younger ages, with more advanced stages, anemia, and a high percentage of bone disease. ISS provides an excellent tool for prognosis purposes. Cytogenetic risk assessment based on FISH should be done for all MM patients from therapeutic implications. We need standardized protocols for bone marrow sample manipulation and processing in order to guarantee good correlation for plasma cells count methods. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1522 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1522/960

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 39 47 Aysun Senturk Yikilmaz Department of Hematology, Bilkent City Hospital, Yıldırım Beyazıt University, Ankara, Turkey Şule Bakanay Department of Hematology, Bilkent City Hospital, Yıldırım Beyazıt University, Ankara, Turkey Duygu Avcı Department of Hematology, Ankara Numune Training and Research Hospital, , Ankara, Turkey Sema Akinci Department of Hematology, Atatürk Training and Research Hospital, Ankara, Turkey Mesude Falay Department of Hematology, Ankara Numune Training and Research Hospital, , Ankara, Turkey Gülsüm Özet Department of Hematology, Ankara Numune Training and Research Hospital, Ankara, Turkey İmdat Dilek Department of Hematology, Atatürk Training and Research Hospital, Ankara, Turkey 2021 06 08 2021 09 06 Background: The transmembrane receptor tyrosine kinase-like orphan receptor 1 (ROR1) has acted on the causation and sustentation of mature B cell lymphomagenesis for chronic lymphocytic leukemia (CLL) cells. The aim of this study was to show whether there is a relationship between the level of ROR1 surface expression in CLL cells and disease findings. Materials and Methods: The level of ROR1 cell surface expression was determined in accordance with the flow cytometric analysis of CLL patients at the first diagnosis time.  2 groups were formed according to the high and low ROR1 levels. The cut-off point to the ROR1 level was calculated for advanced-stage disease by using receiver operating characteristic (ROC) curves. A two-sided p-value <0,05 was considered statistically significant. Results: 108 CLL cases with a median age of 60 were enrolled. The median percentage of ROR1 cell surface marker positivity in the CD5/CD19 positive leukemic cell was 62%. The CLL cases with high ROR1 levels have thrombocytopenia (p=0.042), anemia (p=0.028), and high beta 2 microglobulin value ≥3 mg/dL (p=0.002) and the need for first-line treatment (p=0.043). Conclusion: The poor prognostic parameters such as splenomegaly, anemia, higher beta 2 microglobulin levels, intermediate/advanced RAİ stage disease, and need for first-line treatment had associated high-level ROR 1 expression of our CLL patients. It needs to be investigated for its effect on predicting disease burden and aggressiveness with more comprehensive studies on ROR1 expression levels in CLL cases. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1649 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1649/961

Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 17 1 2023 01 16 48 55 Ria Etikasari Doctoral Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia Tri Andayani Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia Dwi Endarti Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia Kartika Taroeno-Hariadi Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia 2021 01 15 2021 02 07 Background: Several studies showed the superiority of aromatase inhibitor (AI) as first-line therapy for patients with hormone-receptor (HR)-positive breast cancer (BC). For the clinician, studies in the real-world are warranted to determine treatment based on the efficacy of each drug. We conducted a comparison of 5-y disease-free survival (DFS) of each AI in terms of survival benefit. Materials and Methods: We evaluated 450 medical records of postmenopausal women at Dr. Sardjito General Hospital who were diagnosed with HR-positive HER2-negative BC (stage I – III) from January to December 2019 and had undergone surgery, received chemotherapy or radiation therapy, and at least one year of anastrozole, letrozole, or exemestane administration. Kaplan Meier estimation survival curve was used to analyse of survival rate. Result: Of 79 patients meeting inclusion criteria, there were 21.52% distant metastases documented. Time to disease progression of anastrozole, letrozole and exemestane was 49 months, 58 months, and 53 months, respectively. Letrozole was found better than anastrozole (hazard ratio (HR)=4.342, 95% CI 0.95-19.95; p=0.038). Letrozole versus exemestane (HR=2.757, 95% CI 0.53-14.33; p=0,206) and anastrozole versus exemestane (HR=1.652, 95% CI 0.56-4.84; p=0.351) were found not significantly different. 5-y DFS rate of letrozole was better found (87.5%) than exemestane (73.7%) and anastrozole (61,4%). Conclusion: 5-year letrozole administration could be proposed as first-line therapy for postmenopausal women with HR-positive HER2-negative BC. A considerable subject and long-term follow-up are needed for validation. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1529 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1529/962